{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:25:44Z","timestamp":1792063544341,"version":"4.4.0"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008973","name":"University of Kurdistan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.intimp.2021.107836","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T22:40:02Z","timestamp":1625179202000},"page":"107836","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"special_numbering":"C","title":["Interleukin-2 therapy of cancer-clinical perspectives"],"prefix":"10.1016","volume":"98","author":[{"given":"Jamal","family":"Majidpoor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2004-3465","authenticated-orcid":false,"given":"Keywan","family":"Mortezaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.intimp.2021.107836_b0005","doi-asserted-by":"crossref","first-page":"17187","DOI":"10.1002\/jcp.28504","article-title":"NF-\u03baB targeting for overcoming tumor resistance and normal tissues toxicity","volume":"234","author":"Mortezaee","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.intimp.2021.107836_b0010","article-title":"Synergic effects of nanoparticles-mediated hyperthermia in radiotherapy\/chemotherapy of cancer","volume":"119020","author":"Mortezaee","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.intimp.2021.107836_b0015","article-title":"Immune escape: a critical hallmark in solid tumors","volume":"118110","author":"Mortezaee","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.intimp.2021.107836_b0020","article-title":"The efficacy of PD-1\/PD-L1 blockade in cold cancers and future perspectives","volume":"108707","author":"Majidpoor","year":"2021","journal-title":"Clin. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2021.107836_b0025","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.22708","article-title":"Enriched cancer stem cells, dense stroma, and cold immunity: Interrelated events in pancreatic cancer","volume":"35","author":"Mortezaee","year":"2021","journal-title":"J. Biochem. Mol. Toxicol."},{"issue":"7","key":"10.1016\/j.intimp.2021.107836_b0030","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1158\/1078-0432.CCR-11-1823","article-title":"CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma","volume":"18","author":"Prieto","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2021.107836_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.05.076","article-title":"Cancer stem cell (a) symmetry & plasticity: tumorigenesis and therapy relevance","volume":"231","author":"Najafi","year":"2019","journal-title":"Life Sci."},{"issue":"17","key":"10.1016\/j.intimp.2021.107836_b0040","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J clinical oncology"},{"issue":"5","key":"10.1016\/j.intimp.2021.107836_b0045","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/0284186X.2018.1433324","article-title":"A randomized phase II trial of interleukin-2 and interferon-\u03b1 plus bevacizumab versus interleukin-2 and interferon-\u03b1 in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1","volume":"57","author":"Donskov","year":"2018","journal-title":"Acta Oncol."},{"issue":"311","key":"10.1016\/j.intimp.2021.107836_b0050","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac8155","article-title":"IL-2R\u03b1 mediates temporal regulation of IL-2 signaling and enhances immunotherapy","volume":"7","author":"Su","year":"2015","journal-title":"Sci translational med"},{"issue":"6379","key":"10.1016\/j.intimp.2021.107836_b0055","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1126\/science.aar3246","article-title":"Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes","volume":"359","author":"Sockolosky","year":"2018","journal-title":"Science"},{"issue":"574","key":"10.1016\/j.intimp.2021.107836_b0060","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb9283","article-title":"Receptor-gated IL-2 delivery by an anti-human IL-2 antibody activates regulatory T cells in three different species","volume":"12","author":"Karakus","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2021.107836_b0065","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.3389\/fimmu.2018.01683","article-title":"Interleukin (IL)-2 is a key regulator of T helper 1 and T helper 2 cytokine expression in fish: functional characterization of two divergent IL2 paralogs in salmonids","volume":"9","author":"Wang","year":"2018","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2021.107836_b0070","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1002\/cbin.11187","article-title":"Extracellular-signal-regulated kinase\/mitogen-activated protein kinase signaling as a target for cancer therapy: an updated review","volume":"43","author":"Najafi","year":"2019","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.intimp.2021.107836_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.117145","article-title":"Hypoxia induces core-to-edge transition of progressive tumoral cells: A critical review on differential yet corroborative roles for HIF-1\u03b1 and HIF-2\u03b1","volume":"242","author":"Mortezaee","year":"2020","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.intimp.2021.107836_b0080","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/cbin.11506","article-title":"Redox tolerance and metabolic reprogramming in solid tumors","volume":"45","author":"Mortezaee","year":"2021","journal-title":"Cell Biology Interl"},{"key":"10.1016\/j.intimp.2021.107836_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.117049","article-title":"Stromal reprogramming: a target for tumor therapy","volume":"239","author":"Najafi","year":"2019","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.intimp.2021.107836_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-14471-1","article-title":"Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy","volume":"11","author":"Sharma","year":"2020","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.intimp.2021.107836_b0095","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00262-013-1397-7","article-title":"Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response","volume":"62","author":"Camisaschi","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.intimp.2021.107836_b0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-20220-1","article-title":"An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer","volume":"11","author":"Sahin","year":"2020","journal-title":"Nat. Commun."},{"issue":"367","key":"10.1016\/j.intimp.2021.107836_b0105","volume":"8","author":"Arenas-Ramirez","year":"2016","journal-title":"Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2, Science translational medicine"},{"issue":"1","key":"10.1016\/j.intimp.2021.107836_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-020-01447-w","article-title":"Steps in metastasis: an updated review","volume":"38","author":"Majidpoor","year":"2021","journal-title":"Med. Oncol."},{"key":"10.1016\/j.intimp.2021.107836_b0115","doi-asserted-by":"crossref","DOI":"10.2217\/fon-2020-1103","article-title":"Organ tropism in solid tumor metastasis: an updated review","author":"Mortezaee","year":"2021","journal-title":"Future Oncology (0)"},{"issue":"561","key":"10.1016\/j.intimp.2021.107836_b0120","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba5464","article-title":"Interleukin-2 signals converge in a lymphoid\u2013dendritic cell pathway that promotes anticancer immunity","volume":"12","author":"Raeber","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.intimp.2021.107836_b0125","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1007\/s10637-019-00736-0","article-title":"Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials","volume":"37","author":"Martini","year":"2019","journal-title":"Invest. New Drugs"},{"issue":"1","key":"10.1016\/j.intimp.2021.107836_b0130","first-page":"1","article-title":"Multi-cellular natural killer (NK) cell clusters enhance NK cell activation through localizing IL-2 within the cluster","volume":"7","author":"Kim","year":"2017","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.intimp.2021.107836_b0135","doi-asserted-by":"crossref","first-page":"4230","DOI":"10.4049\/jimmunol.169.8.4230","article-title":"Signaling through NK cell-associated CD137 promotes both helper function for CD8+ cytolytic T cells and responsiveness to IL-2 but not cytolytic activity","volume":"169","author":"Wilcox","year":"2002","journal-title":"J Immunology"},{"key":"10.1016\/j.intimp.2021.107836_b0140","doi-asserted-by":"crossref","DOI":"10.1136\/jim-2020-001650","article-title":"Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2","author":"Clark","year":"2021","journal-title":"J Investigative Med"},{"key":"10.1016\/j.intimp.2021.107836_b0145","doi-asserted-by":"crossref","unstructured":"G. Churlaud, C. Abbara, P.-A. Vinot, G. Fourcade, P.-G. Ritvo, R. Lorenzon, M. Rosenzwajg, B. Diquet, D. Klatzmann, Pharmacodynamics of regulatory T cells in mice and humans treated with low-dose IL-2, Journal of Allergy and Clinical Immunology 142(4) (2018) 1344-1346. e3.","DOI":"10.1016\/j.jaci.2018.06.006"},{"issue":"50","key":"10.1016\/j.intimp.2021.107836_b0150","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aba5264","article-title":"An IL-2 mutein engineered to promote expansion of regulatory T cells arrests ongoing autoimmunity in mice","volume":"5","author":"Khoryati","year":"2020","journal-title":"Sci. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2021.107836_b0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-019-0522-3","article-title":"Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition","volume":"7","author":"Buchbinder","year":"2019","journal-title":"J immunotherapy of cancer"},{"issue":"1","key":"10.1016\/j.intimp.2021.107836_b0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CAD.0b013e32835a5ca3","article-title":"Management of toxicities associated with high-dose interleukin-2 and biochemotherapy","volume":"24","author":"Poust","year":"2013","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.intimp.2021.107836_b0165","article-title":"Sequential administration of high-dose interleukin-2 and ipilimumab in patients with metastatic melanoma, American Society of","author":"Patel","year":"2016","journal-title":"Clinical Oncology"},{"issue":"23","key":"10.1016\/j.intimp.2021.107836_b0170","doi-asserted-by":"crossref","first-page":"7199","DOI":"10.1158\/1078-0432.CCR-17-1178","article-title":"Immunomodulation by entinostat in renal cell carcinoma patients receiving high-dose interleukin 2: a multicenter, single-arm, phase I\/II trial (NCI-CTEP# 7870)","volume":"23","author":"Pili","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.intimp.2021.107836_b0175","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00262-016-1854-1","article-title":"Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2","volume":"65","author":"Stenehjem","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"issue":"22","key":"10.1016\/j.intimp.2021.107836_b0180","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.1002\/cncr.31734","article-title":"NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma","volume":"124","author":"Tarhini","year":"2018","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2021.107836_b0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-019-0567-3","article-title":"Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM SM registry","volume":"7","author":"Fishman","year":"2019","journal-title":"J immunotherapy of cancer"},{"issue":"1","key":"10.1016\/j.intimp.2021.107836_b0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-018-5193-9","article-title":"A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma","volume":"18","author":"McQuade","year":"2018","journal-title":"BMC cancer"},{"issue":"12","key":"10.1016\/j.intimp.2021.107836_b0195","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s00262-016-1910-x","article-title":"Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma","volume":"65","author":"Alva","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.intimp.2021.107836_b0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-017-0279-5","article-title":"High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute","volume":"5","author":"Davar","year":"2017","journal-title":"J immunotherapy of cancer"},{"issue":"17","key":"10.1016\/j.intimp.2021.107836_b0205","doi-asserted-by":"crossref","first-page":"5610","DOI":"10.1158\/1078-0432.CCR-08-0116","article-title":"Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines","volume":"14","author":"Smith","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.intimp.2021.107836_b0210","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1158\/1078-0432.CCR-14-1520","article-title":"The high-dose aldesleukin \u201cselect\u201d trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma","volume":"21","author":"McDermott","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2021.107836_b0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-017-0053-3","article-title":"E2112: randomized phase iii trial of endocrine therapy plus entinostat\/placebo in patients with hormone receptor-positive advanced breast cancer","volume":"4","author":"Yeruva","year":"2018","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.intimp.2021.107836_b0220","first-page":"1","article-title":"Angiogenesis as a hallmark of solid tumors-clinical perspectives","author":"Majidpoor","year":"2021","journal-title":"Cellular Oncology"},{"issue":"9","key":"10.1016\/j.intimp.2021.107836_b0225","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s12094-012-0991-z","article-title":"Phase II trial of sequential subcutaneous interleukin-2 plus interferon alpha followed by sorafenib in renal cell carcinoma (RCC)","volume":"15","author":"Maroto","year":"2013","journal-title":"Clin. Transl. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2021.107836_b0230","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.clgc.2016.05.008","article-title":"Axitinib versus sorafenib in first-line metastatic renal cell carcinoma: overall survival from a randomized phase III trial","volume":"15","author":"Hutson","year":"2017","journal-title":"Clinical genitourinary cancer"},{"key":"10.1016\/j.intimp.2021.107836_b0235","article-title":"Immune system in cancer radiotherapy: Resistance mechanisms and therapy perspectives","volume":"103180","author":"Mortezaee","year":"2020","journal-title":"Critical Reviews in Oncology\/Hematology"},{"key":"10.1016\/j.intimp.2021.107836_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119627","article-title":"Myeloid-derived suppressor cells in cancer immunotherapy-clinical perspectives","volume":"277","author":"Mortezaee","year":"2021","journal-title":"Life Sci."},{"issue":"12","key":"10.1016\/j.intimp.2021.107836_b0245","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1158\/2326-6066.CIR-18-0793","article-title":"Phase II trial of ipilimumab with stereotactic radiation therapy for metastatic disease: outcomes, toxicities, and low-dose radiation-related Abscopal responses","volume":"7","author":"Welsh","year":"2019","journal-title":"Cancer immunology research"},{"issue":"39","key":"10.1016\/j.intimp.2021.107836_b0250","doi-asserted-by":"crossref","first-page":"64390","DOI":"10.18632\/oncotarget.10453","article-title":"A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma","volume":"7","author":"Ray","year":"2016","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.intimp.2021.107836_b0255","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB\u2013C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.intimp.2021.107836_b0260","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00262-016-1944-0","article-title":"Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma\u2014safety and efficacy in a phase II study","volume":"66","author":"Weide","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"issue":"22","key":"10.1016\/j.intimp.2021.107836_b0265","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1056\/NEJMoa1012863","article-title":"gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma","volume":"364","author":"Schwartzentruber","year":"2011","journal-title":"New England J Med"},{"issue":"6230","key":"10.1016\/j.intimp.2021.107836_b0270","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.intimp.2021.107836_b0275","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cytogfr.2017.06.003","article-title":"Cytokines for the induction of antitumor effectors: The paradigm of Cytokine-Induced Killer (CIK) cells","volume":"36","author":"Cappuzzello","year":"2017","journal-title":"Cytokine Growth Factor Rev."},{"issue":"6","key":"10.1016\/j.intimp.2021.107836_b0280","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/00002371-200111000-00007","article-title":"Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations","volume":"24","author":"M\u00e4rten","year":"2001","journal-title":"J. Immunother."},{"issue":"9","key":"10.1016\/j.intimp.2021.107836_b0285","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.3390\/cancers12092471","article-title":"Clinical Studies Applying Cytokine-Induced Killer Cells for the Treatment of Renal Cell Carcinoma","volume":"12","author":"Zhang","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2021.107836_b0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-020-06860-y","article-title":"Cytokine-induced killer cell\/dendritic cell combined with cytokine-induced killer cell immunotherapy for treating advanced gastrointestinal cancer","volume":"20","author":"Du","year":"2020","journal-title":"BMC cancer"},{"issue":"9","key":"10.1016\/j.intimp.2021.107836_b0295","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.jcyt.2016.05.015","article-title":"Effectiveness and safety of chemotherapy combined with cytokine-induced killer cell\/dendritic cell\u2013cytokine-induced killer cell therapy for treatment of gastric cancer in China: A systematic review and meta-analysis","volume":"18","author":"Mu","year":"2016","journal-title":"Cytotherapy"},{"issue":"6","key":"10.1016\/j.intimp.2021.107836_b0300","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s12094-018-1968-3","article-title":"Combination of DC\/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: A prospective patients\u2019 preference-based study (PPPS)","volume":"21","author":"Zhao","year":"2019","journal-title":"Clin. Transl. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2021.107836_b0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-023-11764-8","article-title":"Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer","volume":"14","author":"Wang","year":"2014","journal-title":"BMC cancer"},{"issue":"2","key":"10.1016\/j.intimp.2021.107836_b0310","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.canlet.2015.03.043","article-title":"Cytokine induced killer cell-based immunotherapies in patients with different stages of renal cell carcinoma","volume":"362","author":"Zhao","year":"2015","journal-title":"Cancer Lett."},{"issue":"42","key":"10.1016\/j.intimp.2021.107836_b0315","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000008310","article-title":"Effect and safety of cytokine-induced killer (CIK) cell immunotherapy in patients with breast cancer: A meta-analysis","volume":"96","author":"Hu","year":"2017","journal-title":"Medicine"},{"issue":"9","key":"10.1016\/j.intimp.2021.107836_b0320","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1158\/1078-0432.CCR-16-1874","article-title":"FCGR polymorphisms influence response to IL2 in metastatic renal cell carcinoma","volume":"23","author":"Erbe","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.intimp.2021.107836_b0325","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1002\/ijc.31285","article-title":"Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with I g G 1 antibody in patients with gastric or colorectal cancer","volume":"142","author":"Ishikawa","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.intimp.2021.107836_b0330","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3389\/fcimb.2020.00102","article-title":"Memory and memory-like NK cell responses to microbial pathogens","volume":"10","author":"Brillantes","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.intimp.2021.107836_b0335","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.3389\/fimmu.2020.622509","article-title":"Exhausted CD8+ T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy","volume":"11","author":"Jiang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2021.107836_b0340","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.3389\/fimmu.2018.02905","article-title":"Anti-cancer therapies employing IL-2 cytokine tumor targeting: Contribution of innate, adaptive and immunosuppressive cells in the anti-tumor efficacy","volume":"9","author":"Mortara","year":"2018","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2021.107836_b0345","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41590-020-00850-9","article-title":"IL-2 regulates tumor-reactive CD8+ T cell exhaustion by activating the aryl hydrocarbon receptor","volume":"22","author":"Liu","year":"2021","journal-title":"Nat. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2021.107836_b0350","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","article-title":"Biology and regulation of IL-2: from molecular mechanisms to human therapy","volume":"18","author":"Spolski","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2021.107836_b0355","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.immuni.2012.02.012","article-title":"Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation","volume":"36","author":"Ballesteros-Tato","year":"2012","journal-title":"Immunity"},{"issue":"39","key":"10.1016\/j.intimp.2021.107836_b0360","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aaw7636","article-title":"Inhibition of IL-2 responsiveness by IL-6 is required for the generation of GC-TFH cells","volume":"4","author":"Papillion","year":"2019","journal-title":"Sci. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2021.107836_b0365","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1073\/pnas.1814642116","article-title":"IL-15 is a component of the inflammatory milieu in the tumor microenvironment promoting antitumor responses","volume":"116","author":"Carrero","year":"2019","journal-title":"Proceedings National Acad Sci"},{"key":"10.1016\/j.intimp.2021.107836_b0370","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.3389\/fimmu.2019.02741","article-title":"Vaccine-induced antibodies mediate higher antibody-dependent cellular cytotoxicity after interleukin-15 pretreatment of natural killer effector cells","volume":"10","author":"Fisher","year":"2019","journal-title":"Front. Immunol."},{"issue":"22","key":"10.1016\/j.intimp.2021.107836_b0375","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.1158\/1078-0432.CCR-18-0945","article-title":"Phase I trial of ALT-803, a novel recombinant IL15 complex, in patients with advanced solid tumors","volume":"24","author":"Margolin","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"23","key":"10.1016\/j.intimp.2021.107836_b0380","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1182\/blood-2017-12-823757","article-title":"First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation","volume":"131","author":"Romee","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2021.107836_b0385","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","article-title":"Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer","volume":"33","author":"Conlon","year":"2015","journal-title":"J clinical oncology"},{"issue":"4","key":"10.1016\/j.intimp.2021.107836_b0390","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/cmi.2014.13","article-title":"IL-15 trans-presentation regulates homeostasis of CD4+ T lymphocytes","volume":"11","author":"Chen","year":"2014","journal-title":"Cell. Mol. Immunol."},{"issue":"16","key":"10.1016\/j.intimp.2021.107836_b0395","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.1158\/1078-0432.CCR-18-3468","article-title":"IL15 by continuous intravenous infusion to adult patients with solid tumors in a phase I trial induced dramatic NK-cell subset expansion","volume":"25","author":"Conlon","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.intimp.2021.107836_b0400","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/intimm\/dxn022","article-title":"Application of CD27 as a marker for distinguishing human NK cell subsets","volume":"20","author":"Silva","year":"2008","journal-title":"Int. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2021.107836_b0405","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S1470-2045(18)30148-7","article-title":"ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial","volume":"19","author":"Wrangle","year":"2018","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2021.107836_b0410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-11782-w","article-title":"A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control","volume":"10","author":"Sun","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2021.107836_b0415","article-title":"Engineering IL-2 to Give New Life to T Cell Immunotherapy","volume":"72","author":"Overwijk","year":"2020","journal-title":"Annual Review of Med"},{"key":"10.1016\/j.intimp.2021.107836_b0420","doi-asserted-by":"crossref","unstructured":"S.-E. Bentebibel, M.E. Hurwitz, C. Bernatchez, C. Haymaker, C.W. Hudgens, H.M. Kluger, M.T. Tetzlaff, M.A. Tagliaferri, J. Zalevsky, U. Hoch, A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Raf-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors, (2019).","DOI":"10.1158\/2159-8290.CD-18-1495"},{"issue":"6","key":"10.1016\/j.intimp.2021.107836_b0425","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1158\/2159-8290.CD-18-1495","article-title":"A first-in-human study and biomarker analysis of NKTR-214, a novel IL2R\u03b2\u03b3-biased cytokine, in patients with advanced or metastatic solid tumors","volume":"9","author":"Bentebibel","year":"2019","journal-title":"Cancer discovery"},{"issue":"8","key":"10.1016\/j.intimp.2021.107836_b0430","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1158\/2159-8290.CD-19-1510","article-title":"Bempegaldesleukin (NKTR-214) plus nivolumab in patients with advanced solid tumors: phase I dose-escalation study of safety, efficacy, and immune activation (PIVOT-02)","volume":"10","author":"Diab","year":"2020","journal-title":"Cancer discovery"},{"key":"10.1016\/j.intimp.2021.107836_b0435","article-title":"MDNA109: Effect of an interleukin-2 superkine on CD8 T-cell properties in the tumor microenvironment, American Society of","author":"Rafei","year":"2019","journal-title":"Clinical Oncology"},{"issue":"1","key":"10.1016\/j.intimp.2021.107836_b0440","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-12901-3","article-title":"Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist","volume":"11","author":"Parisi","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.intimp.2021.107836_b0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-014-0026-0","article-title":"High dose interleukin-2 (Aldesleukin)-expert consensus on best management practices-2014","volume":"2","author":"Dutcher","year":"2014","journal-title":"J immunotherapy of cancer"},{"issue":"12","key":"10.1016\/j.intimp.2021.107836_b0450","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1182\/blood-2002-10-3089","article-title":"Generation of low-toxicity interleukin-2 fusion proteins devoid of vasopermeability activity","volume":"101","author":"Hu","year":"2003","journal-title":"Blood"},{"issue":"11 Suppl 13","key":"10.1016\/j.intimp.2021.107836_b0455","first-page":"11","article-title":"Managing toxicities of high-dose interleukin-2","volume":"16","author":"Schwartz","year":"2002","journal-title":"Oncology (Williston Park, NY)"},{"issue":"8","key":"10.1016\/j.intimp.2021.107836_b0460","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1007\/s00262-020-02572-1","article-title":"Tumor infiltrating lymphocytes as adjuvant treatment in stage III melanoma patients with only one invaded lymph node after complete resection: results from a multicentre, randomized clinical phase III trial","volume":"69","author":"Khammari","year":"2020","journal-title":"Cancer Immunol. Immunother."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921004720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921004720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T11:24:57Z","timestamp":1747308297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576921004720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":92,"alternative-id":["S1567576921004720"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107836","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin-2 therapy of cancer-clinical perspectives","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107836","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107836"}}